Progress in the pharmacotherapy of gout.
OBJECTIVE
To summarize new knowledge on approved and emerging drugs used to treat hyperuricemia or the clinical manifestations of gout.


RESULTS
Results of several clinical trials provide new data on the efficacy and safety of the approved urate-lowering drugs, allopurinol and febuxostat. New recommendations have been presented on appropriate dosing of colchicine for acute gout flares and potential toxicities of combining colchicine with medications such as clarithromycin. Emerging therapies, including pegloticase, the uricosuric agent RDEA596, and the interleukin-1 inhibitors, rilonacept and canakinumab, have shown promise in early and late phase clinical trials.


CONCLUSIONS
Recent publications demonstrate an opportunity to use existing gout therapies more effectively in order to improve both efficacy and safety. Emerging therapies for gout show promise for unmet needs in selected gout populations.
Sundy
John S
JS
Division of Pulmonary Allergy and Critical Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. john.sundy@duke.edu
D000493:Allopurinol / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003078:Colchicine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000069465:Febuxostat; D006073:Gout / Q000188:drug therapy*; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D014528:Uricosuric Agents / Q000627:therapeutic use
D006074:Gout Suppressants; D011993:Recombinant Fusion Proteins; D013844:Thiazoles; D014528:Uricosuric Agents; D000069465:Febuxostat; D000493:Allopurinol; C531377:rilonacept; D003078:Colchicine